Despite the lack of trials proving the efficacy of DNase in non cystic fibrosis patients, it
is currently heavily used in this population. In fact, per evidence of barcode scanning via
Meditech computer system at OU Medical Center 93% of the DNase prescribed in 2005 was for
non Cystic fibrosis patients with an estimated yearly cost of $341,968.15.In vitro studies
showed that the effect of Dnase was minimal on sputum viscosity when compared to Hypertonic
saline . Furthermore recent studies on hypertonic saline in cystic fibrosis patients showed
that it is an inexpensive and safe therapy when preceded by a bronchodilator in patients
with cystic fibrosis.
We hereby propose a prospective randomized trial to compare the efficacy of hypertonic
saline, DNase, vs. normal saline in the treatment of atelectasis in non cystic fibrosis,
mechanically ventilated patient.
1. Patient on invasive mechanical ventilation
2. New Onset (<48 hours) lobar or multilobar lung atelectasis based on CXR
2. Severe COPD (FEV1<30%)
3. Pneumothorax or massive pleural effusion, thought to be causing the atelectasis
4. Lobar atelectasis secondary to compressive tumor.
5. Severe hypoxemia (PaO2/FiO2 < 75)
6. Hemodynamic Instability
7. Cystic fibrosis patients
8. Allergy to DNase
9. Patients on Acetylcysteine
10. Pregnant women